In Vitro Selection and Characterization of Bacillus anthracis Mutants with High-Level Resistance to Ciprofloxacin-Reference-Cited by-同舟云学术

In Vitro Selection and Characterization of Bacillus anthracis Mutants with High-Level Resistance to Ciprofloxacin

Published:2003-07 Issue:7 Volume:47 Page:2362-2365
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Price Lance B.¹²,Vogler Amy¹,Pearson Talima¹,Busch Joseph D.¹,Schupp James M.¹,Keim Paul¹

Affiliation:

1. Department of Biological Sciences, Northern Arizona University, Flagstaff, Arizona 86011-5640

2. Environmental Health Sciences, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland 21205

Abstract

ABSTRACT Mutants of attenuated Bacillus anthracis with high-level ciprofloxacin resistance were isolated using a three-step in vitro selection. Ciprofloxacin MICs were 0.5 μg/ml for first-step mutants, which had one of two gyrA quinolone resistance-determining region (QRDR) mutations. Ciprofloxacin MICs were 8 and 16 μg/ml for second-step mutants, which had one of three parC QRDR mutations. Ciprofloxacin MICs for third-step mutants were 32 and 64 μg/ml. Mutants for which MICs were 64 μg/ml had one of two additional mutations within the gyrA QRDR or one of two mutations within the gyrB QRDR. Mutants for which MICs were 32 μg/ml had no additional target modifications but showed evidence of enhanced ciprofloxacin efflux.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.47.7.2362-2365.2003

Reference25 articles.

1. Two highly similar multidrug transporters of Bacillus subtilis whose expression is differentially regulated

2. Brook, I., T. B. Elliott, H. I. Pryor II, T. E. Sautter, B. T. Gnade, J. H. Thakar, and G. B. Knudson. 2001. In vitro resistance of Bacillus anthracis Sterne to doxycycline, macrolides and quinolones. Int. J. Antimicrob. Agents18:559-562.

3. Brook, I. 2002. The prophylaxis and treatment of anthrax. Int. J. Antimicrob. Agents20:320-325.

4. Bryskier, A. 2002. Bacillus anthracis and antimicrobial agents. Clin. Microbial. Infect.8:467-478.

5. Antibiotic Susceptibilities of 96 Isolates of Bacillus anthracis Isolated in France between 1994 and 2000

Cited by 103 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genetic basis of clarithromycin resistance in Bacillus anthracis;Microbiology Spectrum;2024-06-04

2. 8-OxoG-Dependent Regulation of Global Protein Responses Leads to Mutagenesis and Stress Survival in Bacillus subtilis;Antioxidants;2024-03-08

3. Efficacy of therapeutically administered gepotidacin in a rabbit model of inhalational anthrax;Antimicrobial Agents and Chemotherapy;2024-03-06

4. Synthetic and natural rubber associated chemicals drive functional and structural changes as well as adaptations to antibiotics in in vitro marine microbiomes;Ecotoxicology and Environmental Safety;2024-03

5. Systems metabolic engineering of the primary and secondary metabolism of Streptomyces albidoflavus enhances production of the reverse antibiotic nybomycin against multi-resistant Staphylococcus aureus;Metabolic Engineering;2024-01